JP7275111B2 - 脂質ナノ粒子の生成方法 - Google Patents
脂質ナノ粒子の生成方法 Download PDFInfo
- Publication number
- JP7275111B2 JP7275111B2 JP2020512372A JP2020512372A JP7275111B2 JP 7275111 B2 JP7275111 B2 JP 7275111B2 JP 2020512372 A JP2020512372 A JP 2020512372A JP 2020512372 A JP2020512372 A JP 2020512372A JP 7275111 B2 JP7275111 B2 JP 7275111B2
- Authority
- JP
- Japan
- Prior art keywords
- lipid
- mir
- optionally substituted
- peg
- glycero
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023076121A JP2023093756A (ja) | 2017-08-31 | 2023-05-02 | 脂質ナノ粒子の生成方法 |
| JP2025072087A JP2025108727A (ja) | 2017-08-31 | 2025-04-24 | 脂質ナノ粒子の生成方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762553088P | 2017-08-31 | 2017-08-31 | |
| US201762553085P | 2017-08-31 | 2017-08-31 | |
| US62/553,085 | 2017-08-31 | ||
| US62/553,088 | 2017-08-31 | ||
| US201762590193P | 2017-11-22 | 2017-11-22 | |
| US62/590,193 | 2017-11-22 | ||
| PCT/US2018/049251 WO2019046809A1 (en) | 2017-08-31 | 2018-08-31 | METHODS OF MANUFACTURING LIPID NANOPARTICLES |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023076121A Division JP2023093756A (ja) | 2017-08-31 | 2023-05-02 | 脂質ナノ粒子の生成方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020532528A JP2020532528A (ja) | 2020-11-12 |
| JP2020532528A5 JP2020532528A5 (enExample) | 2021-10-07 |
| JP7275111B2 true JP7275111B2 (ja) | 2023-05-17 |
Family
ID=63684527
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020512372A Active JP7275111B2 (ja) | 2017-08-31 | 2018-08-31 | 脂質ナノ粒子の生成方法 |
| JP2023076121A Pending JP2023093756A (ja) | 2017-08-31 | 2023-05-02 | 脂質ナノ粒子の生成方法 |
| JP2025072087A Pending JP2025108727A (ja) | 2017-08-31 | 2025-04-24 | 脂質ナノ粒子の生成方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023076121A Pending JP2023093756A (ja) | 2017-08-31 | 2023-05-02 | 脂質ナノ粒子の生成方法 |
| JP2025072087A Pending JP2025108727A (ja) | 2017-08-31 | 2025-04-24 | 脂質ナノ粒子の生成方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11744801B2 (enExample) |
| EP (1) | EP3675817A1 (enExample) |
| JP (3) | JP7275111B2 (enExample) |
| CN (1) | CN111315359A (enExample) |
| AU (1) | AU2018326799A1 (enExample) |
| CA (1) | CA3073211A1 (enExample) |
| MX (1) | MX2020002348A (enExample) |
| WO (1) | WO2019046809A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023093756A (ja) * | 2017-08-31 | 2023-07-04 | モデルナティエックス インコーポレイテッド | 脂質ナノ粒子の生成方法 |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3134131T3 (en) | 2014-04-23 | 2022-02-07 | Modernatx Inc | Nucleic acid vaccines |
| WO2017020026A1 (en) | 2015-07-30 | 2017-02-02 | Modernatx, Inc. | Concatemeric peptide epitopes rnas |
| RS63030B1 (sr) | 2015-09-17 | 2022-04-29 | Modernatx Inc | Jedinjenja i kompozicije za intracelularno isporučivanje terapeutskih sredstava |
| MD3718565T2 (ro) | 2015-10-22 | 2022-09-30 | Modernatx Inc | Vaccinuri împotriva virusului respirator |
| JP7114465B2 (ja) | 2015-12-22 | 2022-08-08 | モデルナティエックス インコーポレイテッド | 薬剤の細胞内送達のための化合物および組成物 |
| US12128113B2 (en) | 2016-05-18 | 2024-10-29 | Modernatx, Inc. | Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome |
| JP6983455B2 (ja) | 2016-09-14 | 2021-12-17 | モデルナティーエックス， インコーポレイテッド | 高純度ｒｎａ組成物及びその調製のための方法 |
| CN110167587A (zh) | 2016-11-11 | 2019-08-23 | 摩登纳特斯有限公司 | 流感疫苗 |
| WO2018170245A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| KR20190132405A (ko) | 2017-03-15 | 2019-11-27 | 모더나티엑스, 인크. | 치료제의 세포내 전달을 위한 화합물 및 조성물 |
| ES3020935T3 (en) | 2017-03-15 | 2025-05-23 | Modernatx Inc | Lipid nanoparticle formulation |
| WO2018170270A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
| US11752206B2 (en) | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
| CA3056133A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Crystal forms of amino lipids |
| WO2018187590A1 (en) | 2017-04-05 | 2018-10-11 | Modernatx, Inc. | Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins |
| US12077501B2 (en) | 2017-06-14 | 2024-09-03 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| WO2018232357A1 (en) | 2017-06-15 | 2018-12-20 | Modernatx, Inc. | Rna formulations |
| WO2019036683A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | ANALYTICAL METHODS BY HPLC |
| CN111212905A (zh) | 2017-08-18 | 2020-05-29 | 摩登纳特斯有限公司 | Rna聚合酶变体 |
| WO2019036685A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | METHODS FOR HPLC ANALYSIS |
| WO2019148101A1 (en) | 2018-01-29 | 2019-08-01 | Modernatx, Inc. | Rsv rna vaccines |
| JP7379776B2 (ja) | 2018-04-29 | 2023-11-15 | プレシジョン ナノシステムズ ユーエルシー | 耐性細胞型をトランスフェクトするための組成物 |
| WO2020061367A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| AU2019345067A1 (en) | 2018-09-19 | 2021-04-08 | Modernatx, Inc. | High-purity peg lipids and uses thereof |
| US12151029B2 (en) | 2018-09-19 | 2024-11-26 | Modernatx, Inc. | PEG lipids and uses thereof |
| WO2020061457A1 (en) | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| CN113166783B (zh) | 2018-10-09 | 2024-10-11 | 不列颠哥伦比亚大学 | 包含无有机溶剂和去污剂的转染活性囊泡的组合物和系统以及与之相关的方法 |
| KR20210090634A (ko) * | 2018-10-19 | 2021-07-20 | 트랜슬레이트 바이오 인코포레이티드 | 전령 rna의 무펌프 캡슐화 |
| JP2022521094A (ja) | 2019-02-20 | 2022-04-05 | モデルナティエックス インコーポレイテッド | 共転写キャッピング用ｒｎａポリメラーゼバリアント |
| CN113874502A (zh) | 2019-03-11 | 2021-12-31 | 摩登纳特斯有限公司 | 补料分批体外转录方法 |
| WO2020190750A1 (en) | 2019-03-15 | 2020-09-24 | Modernatx, Inc. | Hiv rna vaccines |
| CA3142949A1 (en) * | 2019-06-14 | 2020-12-17 | Dnalite Therapeutics, Inc. | Compositions and methods for biological delivery vehicles |
| MX2022003269A (es) | 2019-09-19 | 2022-07-04 | Modernatx Inc | Compuestos lipidicos de cola ramificada y composiciones para la administracion intracelular de agentes terapeuticos. |
| CA3155015A1 (en) | 2019-09-19 | 2021-03-25 | Modernatx, Inc. | Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents |
| WO2021055609A1 (en) | 2019-09-20 | 2021-03-25 | Translate Bio, Inc. | Mrna encoding engineered cftr |
| US20240293317A1 (en) * | 2020-04-20 | 2024-09-05 | Board Of Regents, The University Of Texas System | Lipid nanoparticle (lnp) delivery systems and uses thereof |
| WO2022010764A1 (en) * | 2020-07-06 | 2022-01-13 | Vivtex Corporation | Mucopenetrating formulations |
| CN116916896A (zh) * | 2020-08-06 | 2023-10-20 | 摩登纳特斯有限公司 | 制备脂质纳米颗粒的方法 |
| TW202220637A (zh) * | 2020-08-06 | 2022-06-01 | 美商現代公司 | 製備脂質奈米顆粒之方法 |
| EP4213882A4 (en) | 2020-09-15 | 2025-02-26 | Verve Therapeutics, Inc. | LIPID FORMULATIONS FOR GENE EDITING |
| CZ310613B6 (cs) | 2020-09-23 | 2026-01-28 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Lipidoidy pro transfekci nukleových kyselin a jejich použití |
| KR20230118715A (ko) | 2020-10-14 | 2023-08-11 | 조지 메이슨 리서치 파운데이션 인코포레이티드 | 이온화 가능 지질 및 이의 제조 및 사용 방법 |
| CA3200234A1 (en) | 2020-11-25 | 2022-06-02 | Daryl C. Drummond | Lipid nanoparticles for delivery of nucleic acids, and related methods of use |
| AU2022206676A1 (en) * | 2021-01-06 | 2023-08-24 | Elevatebio Technologies, Inc. | Encapsulated rna polynucleotides and methods of use |
| WO2022150717A1 (en) | 2021-01-11 | 2022-07-14 | Modernatx, Inc. | Seasonal rna influenza virus vaccines |
| EP4291201A4 (en) * | 2021-02-10 | 2025-04-16 | ElevateBio Technologies, Inc. | Compounds, compositions, and methods of using thereof |
| AU2022245247A1 (en) * | 2021-03-24 | 2023-10-05 | Modernatx, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
| US20240165044A1 (en) * | 2021-04-22 | 2024-05-23 | Inventage Lab Inc. | Lipid nanoparticle preparation method and preparation apparatus therefor |
| EP4329731A1 (en) * | 2021-04-29 | 2024-03-06 | ModernaTX, Inc. | Lyophilization methods for preparing lipid formulated therapeutics |
| US20220363937A1 (en) | 2021-05-14 | 2022-11-17 | Armstrong World Industries, Inc. | Stabilization of antimicrobial coatings |
| CZ310443B6 (cs) | 2021-07-19 | 2025-06-25 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití |
| CN115745942B (zh) * | 2021-09-03 | 2025-06-10 | 广州谷森制药有限公司 | 阳离子脂质化合物 |
| CN115772089B (zh) * | 2021-09-07 | 2025-06-10 | 广州谷森制药有限公司 | 阳离子脂质化合物 |
| CN113908292B (zh) * | 2021-10-13 | 2022-08-16 | 南京吉迈生物技术有限公司 | 靶向物介导的核酸纳米制剂及其制备方法 |
| CN113941011A (zh) * | 2021-10-15 | 2022-01-18 | 浙江汇科泽华生物技术有限公司 | 一种含可离子化阳离子脂质的纳米脂质体颗粒及制备方法 |
| CN114191561B (zh) * | 2021-12-15 | 2022-08-02 | 武汉滨会生物科技股份有限公司 | 一种可离子化脂质化合物在核酸药物递送系统中的应用 |
| CN114163345B (zh) * | 2021-12-15 | 2022-07-26 | 武汉滨会生物科技股份有限公司 | 一种可离子化脂质化合物及核酸体外细胞转染试剂 |
| US12529047B1 (en) | 2021-12-21 | 2026-01-20 | Modernatx, Inc. | mRNA quantification methods |
| CA3241492A1 (en) * | 2021-12-23 | 2023-06-29 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compound and lipid nanoparticle composition |
| CN114656422B (zh) * | 2022-04-22 | 2023-05-23 | 重庆理工大学 | 一种新型氮杂冠醚化合物及其阳离子脂质体、制备方法与应用 |
| CN116969851A (zh) | 2022-04-29 | 2023-10-31 | 北京剂泰医药科技有限公司 | 可电离脂质化合物 |
| CN115887674B (zh) * | 2022-04-29 | 2023-08-25 | 北京剂泰医药科技有限公司 | 脂质纳米颗粒 |
| EP4529472A1 (en) | 2022-05-23 | 2025-04-02 | Logicbio Therapeutics, Inc. | Gene therapy compositions and methods of use thereof |
| EP4531819A2 (en) | 2022-05-25 | 2025-04-09 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids and methods of use thereof |
| WO2024028492A1 (en) * | 2022-08-04 | 2024-02-08 | Sanofi | Quantitative assessment of rna encapsulation |
| CN115634293A (zh) * | 2022-09-27 | 2023-01-24 | 石河子大学 | 一种靶向递送抗肿瘤药物的纳米载体的制备方法和应用 |
| WO2024085149A1 (ja) * | 2022-10-18 | 2024-04-25 | 第一三共株式会社 | テイラー反応装置及びカプセル粒子の製造方法 |
| US20240156733A1 (en) * | 2022-11-05 | 2024-05-16 | CELESTIAL THERAPEUTICS Inc. | Methods of preparation of novel pan tlr antagonistic liposomal-lnp formulations and uses thereof |
| CN115677518B (zh) * | 2023-01-05 | 2023-04-14 | 北京悦康科创医药科技股份有限公司 | 用于递送核酸的可电离阳离子脂质化合物和组合物及用途 |
| CN116178193B (zh) * | 2023-01-05 | 2023-07-28 | 北京悦康科创医药科技股份有限公司 | 高效低毒且稳定性表达的阳离子脂质化合物及其组合物 |
| CN116199646B (zh) * | 2023-03-07 | 2024-01-26 | 山东大学 | 一种基于Tris的可电离脂质及其制备方法与应用 |
| CN119143620A (zh) | 2023-06-16 | 2024-12-17 | 北京剂泰医药科技有限公司 | 一种快速代谢的脂质化合物 |
| JPWO2025022920A1 (enExample) | 2023-07-26 | 2025-01-30 | ||
| CN121729225A (zh) * | 2023-08-25 | 2026-03-24 | 埃泽瑞斯公司 | 具有增强药物应用的特定表面活性剂性质的稳定脂质和类脂质纳米颗粒制剂 |
| WO2025096681A1 (en) | 2023-10-31 | 2025-05-08 | Tiba Biotech Llc | Novel gene delivery agents |
| CN117229160B (zh) * | 2023-11-13 | 2024-03-08 | 北京悦康科创医药科技股份有限公司 | 三酯类阳离子脂质化合物、包含其的组合物及用途 |
| WO2025133115A1 (en) | 2023-12-21 | 2025-06-26 | Ose Immunotherapeutics | Lipid-based nanoparticles comprising il-35 |
| WO2025217298A1 (en) * | 2024-04-10 | 2025-10-16 | Georgia Tech Research Corporation | Novel lipids containing diketopiperazine core, lipid nanoparticle containing thereof, and methods of using thereof |
| US20260014077A1 (en) * | 2024-07-10 | 2026-01-15 | Tiba Biotech Llc | Novel methods to enhance gene delivery |
| CN119174826A (zh) * | 2024-08-09 | 2024-12-24 | 中日友好医院(中日友好临床医学研究所) | 提高脂质纳米颗粒递送效率的方法、制备纳米载体及应用 |
| WO2026093414A1 (en) | 2024-10-30 | 2026-05-07 | Ose Immunotherapeutics | Lipid-based nanoparticles comprising membrane il-35 |
| CN120305220A (zh) * | 2025-06-05 | 2025-07-15 | 郑州大学第一附属医院 | 一种脾脏靶向脂质纳米颗粒及其应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012505913A (ja) | 2008-10-16 | 2012-03-08 | マリーナ バイオテック，インコーポレイテッド | 遺伝子発現を抑制する治療におけるリポソームによる効率的な送達のプロセスおよび組成物 |
| JP2016515815A (ja) | 2013-03-15 | 2016-06-02 | ザ ユニバーシティ オブ ブリティッシュ コロンビア | 形質移入用の脂質ナノ粒子および関連方法 |
| JP2016535729A (ja) | 2013-10-22 | 2016-11-17 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | フェニルケトン尿症のためのｍＲＮＡ療法 |
| JP2016540769A (ja) | 2013-12-05 | 2016-12-28 | サイレンス・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 肺特異的送達用手段 |
Family Cites Families (569)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4270537A (en) | 1979-11-19 | 1981-06-02 | Romaine Richard A | Automatic hypodermic syringe |
| US5171568A (en) | 1984-04-06 | 1992-12-15 | Chiron Corporation | Recombinant herpes simplex gb-gd vaccine |
| US4857319A (en) | 1985-01-11 | 1989-08-15 | The Regents Of The University Of California | Method for preserving liposomes |
| US5223263A (en) | 1988-07-07 | 1993-06-29 | Vical, Inc. | Liponucleotide-containing liposomes |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| US4886499A (en) | 1986-12-18 | 1989-12-12 | Hoffmann-La Roche Inc. | Portable injection appliance |
| GB8704027D0 (en) | 1987-02-20 | 1987-03-25 | Owen Mumford Ltd | Syringe needle combination |
| US4940460A (en) | 1987-06-19 | 1990-07-10 | Bioject, Inc. | Patient-fillable and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4946683A (en) | 1987-11-18 | 1990-08-07 | Vestar, Inc. | Multiple step entrapment/loading procedure for preparing lipophilic drug-containing liposomes |
| US5339163A (en) | 1988-03-16 | 1994-08-16 | Canon Kabushiki Kaisha | Automatic exposure control device using plural image plane detection areas |
| FR2638359A1 (fr) | 1988-11-03 | 1990-05-04 | Tino Dalto | Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau |
| US5049392A (en) | 1989-01-18 | 1991-09-17 | The Liposome Company, Inc. | Osmotically dependent vesicles |
| EP0737750B1 (en) | 1989-03-21 | 2003-05-14 | Vical, Inc. | Expression of exogenous polynucleotide sequences in a vertebrate |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5194654A (en) | 1989-11-22 | 1993-03-16 | Vical, Inc. | Lipid derivatives of phosphonoacids for liposomal incorporation and method of use |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5190521A (en) | 1990-08-22 | 1993-03-02 | Tecnol Medical Products, Inc. | Apparatus and method for raising a skin wheal and anesthetizing skin |
| US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
| FR2676072B1 (fr) | 1991-05-03 | 1994-11-18 | Transgene Sa | Vecteur de delivrance d'arn. |
| ATE132742T1 (de) | 1991-08-16 | 1996-01-15 | Vical Inc | Zusammensetzung und verfahren zur behandlung von zystischer fibrose |
| GB9118204D0 (en) | 1991-08-23 | 1991-10-09 | Weston Terence E | Needle-less injector |
| SE9102652D0 (sv) | 1991-09-13 | 1991-09-13 | Kabi Pharmacia Ab | Injection needle arrangement |
| US5256555A (en) | 1991-12-20 | 1993-10-26 | Ambion, Inc. | Compositions and methods for increasing the yields of in vitro RNA transcription and other polynucleotide synthetic reactions |
| JPH07503372A (ja) | 1992-01-23 | 1995-04-13 | バイカル・インコーポレイテッド | 生体外遺伝子導入 |
| US5328483A (en) | 1992-02-27 | 1994-07-12 | Jacoby Richard M | Intradermal injection device with medication and needle guard |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
| US5334144A (en) | 1992-10-30 | 1994-08-02 | Becton, Dickinson And Company | Single use disposable needleless injector |
| WO1995024176A1 (en) | 1994-03-07 | 1995-09-14 | Bioject, Inc. | Ampule filling device |
| US5466220A (en) | 1994-03-08 | 1995-11-14 | Bioject, Inc. | Drug vial mixing and transfer device |
| US5807718A (en) | 1994-12-02 | 1998-09-15 | The Scripps Research Institute | Enzymatic DNA molecules |
| US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
| US5981501A (en) * | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
| US20050287540A1 (en) | 1995-09-27 | 2005-12-29 | Murphy Brian R | Production of attenuated negative stranded RNA virus vaccines from cloned nucleotide sequences |
| US5893397A (en) | 1996-01-12 | 1999-04-13 | Bioject Inc. | Medication vial/syringe liquid-transfer apparatus |
| WO1997030064A1 (en) | 1996-02-16 | 1997-08-21 | Stichting Rega Vzw | Hexitol containing oligonucleotides and their use in antisense strategies |
| GB9607549D0 (en) | 1996-04-11 | 1996-06-12 | Weston Medical Ltd | Spring-powered dispensing device |
| US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
| WO1999014346A2 (en) | 1997-09-19 | 1999-03-25 | Sequitur, Inc. | SENSE mRNA THERAPY |
| WO1999022009A1 (en) | 1997-10-24 | 1999-05-06 | Megabios Corporation | Methods for preparing polynucleotide transfection complexes |
| AU744755B2 (en) | 1997-11-12 | 2002-03-07 | Brigham And Women's Hospital | The translation enhancer element of the human amyloid precursor protein gene |
| IT1298087B1 (it) | 1998-01-08 | 1999-12-20 | Fiderm S R L | Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni |
| US6432925B1 (en) | 1998-04-16 | 2002-08-13 | John Wayne Cancer Institute | RNA cancer vaccine and methods for its use |
| US7094423B1 (en) | 1999-07-15 | 2006-08-22 | Inex Pharmaceuticals Corp. | Methods for preparation of lipid-encapsulated therapeutic agents |
| ES2235916T3 (es) | 1999-07-15 | 2005-07-16 | Inex Pharmaceuticals Corp. | Preparacion de agentes terapeuticos de encapsulacion lipidica. |
| WO2001023002A1 (en) | 1999-09-30 | 2001-04-05 | National Jewish Medical And Research Center | Method for inhibition of pathogenic microorganisms |
| US6831072B2 (en) | 1999-10-29 | 2004-12-14 | Cygene, Inc. | Compositions and methods of synthesis and use of novel nucleic acid structures |
| US7468275B2 (en) | 2000-01-28 | 2008-12-23 | The Scripps Research Institute | Synthetic internal ribosome entry sites and methods of identifying same |
| EP1259602A1 (en) | 2000-01-28 | 2002-11-27 | The Scripps Research Institute | Methods of identifying synthetic transcriptional and translational regulatory elements, and compositions relating to same |
| US20040142474A1 (en) | 2000-09-14 | 2004-07-22 | Expression Genetics, Inc. | Novel cationic lipopolymer as a biocompatible gene delivery agent |
| US6696038B1 (en) | 2000-09-14 | 2004-02-24 | Expression Genetics, Inc. | Cationic lipopolymer as biocompatible gene delivery agent |
| US20030165849A1 (en) | 2000-11-28 | 2003-09-04 | Biliang Zhang | Methods and reagents for introducing a sulfhydryl group into the 5'-terminus of RNA |
| DE10109897A1 (de) | 2001-02-21 | 2002-11-07 | Novosom Ag | Fakultativ kationische Liposomen und Verwendung dieser |
| CA2449054C (en) | 2001-05-30 | 2011-01-04 | The Scripps Research Institute | Integrin targeting liposome for nucleic acid delivery |
| EP1903054A3 (de) | 2001-06-05 | 2008-07-23 | CureVac GmbH | Stabilisierte mRNA mit erhöhtem G/C-Gehalt und optimierter Codon Usage für die Gentherapie |
| CA2462144C (en) | 2001-09-28 | 2016-09-20 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Micro-rna molecules |
| DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
| US20050222064A1 (en) | 2002-02-20 | 2005-10-06 | Sirna Therapeutics, Inc. | Polycationic compositions for cellular delivery of polynucleotides |
| CA2480775C (en) | 2002-04-04 | 2016-05-31 | Coley Pharmaceutical Gmbh | Immunostimulatory g,u-containing oligoribonucleotides |
| EP1509203B1 (en) | 2002-05-15 | 2016-04-13 | California Pacific Medical Center | Delivery of nucleic acid-like compounds |
| EP1519714B1 (en) | 2002-06-28 | 2010-10-20 | Protiva Biotherapeutics Inc. | Method and apparatus for producing liposomes |
| DE10229872A1 (de) | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immunstimulation durch chemisch modifizierte RNA |
| EP1873180B1 (en) | 2002-08-14 | 2014-05-07 | Novartis AG | Ophthalmic device made from a radiation-curable prepolymer |
| US8426194B2 (en) | 2003-01-21 | 2013-04-23 | Ptc Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating VEGF expression |
| SG190613A1 (en) | 2003-07-16 | 2013-06-28 | Protiva Biotherapeutics Inc | Lipid encapsulated interfering rna |
| EP2530157B1 (en) | 2003-07-31 | 2016-09-28 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of miRNAs |
| DE10335833A1 (de) | 2003-08-05 | 2005-03-03 | Curevac Gmbh | Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie |
| JP2007509040A (ja) | 2003-10-11 | 2007-04-12 | イネックス ファーマシューティカルズ コーポレイション | 先天性免疫及び抗体依存性細胞傷害を強化するための方法及び組成物 |
| WO2005065721A2 (en) | 2003-12-30 | 2005-07-21 | Board Of Regents, The University Of Texas System | Use of an anti-inflammatory compound for the reduction of inflammation secondary to the administration of a lipid-nucleic acid complex |
| ES2246694B1 (es) | 2004-04-29 | 2007-05-01 | Instituto Cientifico Y Tecnologico De Navarra, S.A. | Nanoparticulas pegiladas. |
| WO2005120152A2 (en) | 2004-06-07 | 2005-12-22 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use |
| ATE536418T1 (de) | 2004-06-07 | 2011-12-15 | Protiva Biotherapeutics Inc | Lipidverkapselte interferenz-rna |
| DE102004042546A1 (de) | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Kombinationstherapie zur Immunstimulation |
| US8663599B1 (en) | 2004-10-05 | 2014-03-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| EP1815206B1 (en) | 2004-10-13 | 2016-04-06 | PTC Therapeutics, Inc. | Compounds for nonsense suppression, and methods for their use |
| JP2008520741A (ja) | 2004-11-23 | 2008-06-19 | ピーティーシー セラピューティクス， インコーポレイテッド | 翻訳制御によるｖｅｇｆ生成を阻害するための活性因子としてのテトラヒドロカルバゾール |
| ES2407979T3 (es) | 2004-12-10 | 2013-06-17 | Kala Pharmaceuticals, Inc. | Copolímeros de bloques de poli(éter-anhídrido) funcionalizados |
| DE102005023170A1 (de) | 2005-05-19 | 2006-11-23 | Curevac Gmbh | Optimierte Formulierung für mRNA |
| HUE043492T2 (hu) | 2005-08-23 | 2019-08-28 | Univ Pennsylvania | Módosított nukleozidokat tartalmazó RNS és eljárások az alkalmazására |
| CA2620420A1 (en) | 2005-08-24 | 2007-03-01 | The Scripps Research Institute | Translation enhancer-element dependent vector systems |
| WO2007069068A2 (en) | 2005-12-16 | 2007-06-21 | Diatos | Cell penetrating peptide conjugates for delivering nucleic acids into cells |
| EP2484782B1 (en) | 2006-01-05 | 2015-11-18 | The Ohio State University Research Foundation | MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers |
| CN101384273B (zh) | 2006-01-05 | 2013-07-10 | 俄亥俄州立大学研究基金会 | 胰腺内分泌和腺泡肿瘤中的微小rna表达异常 |
| DE102006007433A1 (de) | 2006-02-17 | 2007-08-23 | Curevac Gmbh | Adjuvanz in Form einer Lipid-modifizierten Nukleinsäure |
| ES2448491T3 (es) | 2006-03-02 | 2014-03-14 | The Ohio State University Research Foundation | Perfil de expresión de microARN asociado con cáncer de páncreas |
| CA2648099C (en) | 2006-03-31 | 2012-05-29 | The Brigham And Women's Hospital, Inc | System for targeted delivery of therapeutic agents |
| WO2008016473A2 (en) | 2006-07-28 | 2008-02-07 | Applera Corporation | Dinucleotide mrna cap analogs |
| JP2010507361A (ja) | 2006-07-31 | 2010-03-11 | キュアバック ゲーエムベーハー | 具体的には免疫刺激剤／アジュバントとしての、一般式（Ｉ）：ＧｌＸｍＧｎ、または一般式（ＩＩ）：ＣｌＸｍＣｎで表される核酸 |
| WO2008036765A2 (en) | 2006-09-19 | 2008-03-27 | Asuragen, Inc. | Micrornas differentially expressed in pancreatic diseases and uses thereof |
| WO2008042973A2 (en) | 2006-10-03 | 2008-04-10 | Alnylam Pharmaceuticals, Inc. | Lipid containing formulations |
| CA2665343C (en) | 2006-10-05 | 2014-12-16 | The Johns Hopkins University | Water-dispersible oral, parenteral, and topical formulations for poorly water soluble drugs using smart polymeric nanoparticles |
| DE102006051516A1 (de) | 2006-10-31 | 2008-05-08 | Curevac Gmbh | (Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins |
| US8252538B2 (en) | 2006-11-01 | 2012-08-28 | The Ohio State University | MicroRNA expression signature for predicting survival and metastases in hepatocellular carcinoma |
| PL2121011T3 (pl) | 2006-12-06 | 2014-10-31 | Novartis Ag | Szczepionki zawierające antygeny czterech szczepów wirusa grypy |
| CN101622348A (zh) | 2006-12-08 | 2010-01-06 | 奥斯瑞根公司 | 作为治疗性干预靶标的miR-20调节的基因和途径 |
| DE102006061015A1 (de) | 2006-12-22 | 2008-06-26 | Curevac Gmbh | Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC |
| AU2007342345B9 (en) | 2006-12-28 | 2013-09-12 | The Trustees Of The University Of Pennsylvania | Herpes Simplex Virus combined subunit vaccines and methods of use thereof |
| DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| GB0700914D0 (en) | 2007-01-18 | 2007-02-28 | Animal Health Inst | Polynucleotides and uses thereof |
| JP2010519203A (ja) | 2007-02-16 | 2010-06-03 | メルク・シャープ・エンド・ドーム・コーポレイション | 生物活性分子の活性を強化するための組成物及び方法 |
| WO2008127688A1 (en) | 2007-04-13 | 2008-10-23 | Hart Communication Foundation | Synchronizing timeslots in a wireless communication protocol |
| LT2494993T (lt) | 2007-05-04 | 2018-12-27 | Marina Biotech, Inc. | Aminorūgščių lipidai ir jų panaudojimas |
| US8415096B2 (en) | 2007-05-23 | 2013-04-09 | University Of South Florida | Micro-RNAs modulating immunity and inflammation |
| US20090099034A1 (en) | 2007-06-07 | 2009-04-16 | Wisconsin Alumni Research Foundation | Reagents and Methods for miRNA Expression Analysis and Identification of Cancer Biomarkers |
| US9144546B2 (en) | 2007-08-06 | 2015-09-29 | Clsn Laboratories, Inc. | Nucleic acid-lipopolymer compositions |
| US20090042825A1 (en) | 2007-08-06 | 2009-02-12 | Majed Matar | Composition, method of preparation & application of concentrated formulations of condensed nucleic acids with a cationic lipopolymer |
| AU2008290545A1 (en) | 2007-08-23 | 2009-02-26 | Novartis Ag | Methods for detecting oligonucleotides |
| WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| SI2644192T1 (sl) | 2007-09-28 | 2017-08-31 | Pfizer Inc. | Ciljanje rakavih celic z uporabo nanodelcev |
| CA2917512C (en) | 2007-10-12 | 2025-08-05 | President And Fellows Of Harvard College | VACCINE NANOTECHNOLOGY |
| EP2222709B1 (en) | 2007-11-30 | 2016-11-23 | Glaxo Group Limited | Antigen-binding constructs |
| CN101918594A (zh) | 2007-11-30 | 2010-12-15 | 俄亥俄州立大学研究基金会 | 肺癌中外周血中的微rna表达特征谱和靶向 |
| CN103911378A (zh) | 2007-12-11 | 2014-07-09 | 斯克利普斯研究所 | 涉及mRNA翻译增强因子的组合物和方法 |
| CA2710983A1 (en) | 2007-12-27 | 2009-10-01 | The Ohio State University Research Foundation | Lipid nanoparticle compositions and methods of making and using the same |
| CN101932707B (zh) | 2008-01-31 | 2013-08-21 | 库瑞瓦格有限责任公司 | 作为免疫刺激剂/佐剂的式(I)(NuGlXmGnNv)a的核酸及其衍生物 |
| WO2009100430A2 (en) | 2008-02-08 | 2009-08-13 | Asuragen, Inc | miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS |
| CA2717026A1 (en) | 2008-02-28 | 2009-09-03 | The Ohio State University Research Foundation | Microrna signatures associated with human chronic lymphocytic leukemia (ccl) and uses thereof |
| NZ588583A (en) * | 2008-04-15 | 2012-08-31 | Protiva Biotherapeutics Inc | Novel lipid formulations for nucleic acid delivery |
| WO2009127230A1 (en) | 2008-04-16 | 2009-10-22 | Curevac Gmbh | MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION |
| EP2112235A1 (en) | 2008-04-24 | 2009-10-28 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Compositions and methods for microRNA expression profiling of nasopharyngeal carcinoma |
| CN102036652B (zh) | 2008-04-25 | 2016-04-13 | 西北大学 | 适于螯合胆甾醇的纳米结构 |
| US8697098B2 (en) | 2011-02-25 | 2014-04-15 | South Dakota State University | Polymer conjugated protein micelles |
| ES2404131T3 (es) | 2008-05-13 | 2013-05-24 | University Of Washington | Copolímeros de dibloques y sus complejos con polinucleótidos para el suministro en células |
| PL215513B1 (pl) | 2008-06-06 | 2013-12-31 | Univ Warszawski | Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka |
| TWI451876B (zh) | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
| WO2010005726A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences Inc. | Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same |
| EA020954B1 (ru) | 2008-06-16 | 2015-03-31 | Бинд Терапьютикс, Инк. | Загруженные лекарственным средством полимерные наночастицы, фармацевтическая композиция и способ лечения рака |
| WO2010018563A2 (en) | 2008-08-12 | 2010-02-18 | Rosetta Genomics Ltd. | Compositions and methods for the prognosis of lymphoma |
| WO2010033906A2 (en) | 2008-09-19 | 2010-03-25 | President And Fellows Of Harvard College | Efficient induction of pluripotent stem cells using small molecule compounds |
| WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| JP5777519B2 (ja) | 2008-10-09 | 2015-09-09 | テクミラ ファーマシューティカルズ コーポレイション | 改良されたアミノ脂質および核酸の送達方法 |
| MX2011004859A (es) | 2008-11-07 | 2011-08-03 | Massachusetts Inst Technology | Lipidoides de aminoalcohol y usos de los mismos. |
| EP4241767B1 (en) | 2008-11-10 | 2024-10-23 | Arbutus Biopharma Corporation | Novel lipids and compositions for the delivery of therapeutics |
| WO2010057203A2 (en) | 2008-11-17 | 2010-05-20 | The Board Of Regents Of The University Of Texas System | Hdl particles for delivery of nucleic acids |
| EP2358902A1 (en) | 2008-12-10 | 2011-08-24 | Universität Regensburg | Compositions and methods for micro-rna expression profiling of cancer stem cells |
| WO2010068866A2 (en) | 2008-12-12 | 2010-06-17 | Bind Biosciences | Therapeutic particles suitable for parenteral administration and methods of making and using same |
| US20120101148A1 (en) | 2009-01-29 | 2012-04-26 | Alnylam Pharmaceuticals, Inc. | lipid formulation |
| WO2010088927A1 (en) | 2009-02-09 | 2010-08-12 | Curevac Gmbh | Use of pei for the improvement of endosomal release and expression of transfected nucleic acids, complexed with cationic or polycationic compounds |
| AU2010223967B2 (en) | 2009-03-12 | 2015-07-30 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes |
| AU2010226434A1 (en) | 2009-03-20 | 2011-10-13 | Egen, Inc. | Polyamine derivatives |
| WO2010111290A1 (en) | 2009-03-23 | 2010-09-30 | University Of Utah Research Foundation | Methods and compositions related to modified guanine bases for controlling off-target effects in rna interference |
| SG176553A1 (en) | 2009-05-05 | 2012-01-30 | Muthiah Manoharan | Lipid compositions |
| WO2010129860A2 (en) | 2009-05-08 | 2010-11-11 | The Ohio State University Research Foundation | Microrna expression profiling and targeting in chronic obstructive pulmonary disease (copd) lung tissue and methods of use thereof |
| US12371522B2 (en) | 2011-10-12 | 2025-07-29 | The Johns Hopkins University | Bioreducible poly (beta-amino ester)s for siRNA delivery |
| TR201811076T4 (tr) | 2009-06-10 | 2018-08-27 | Arbutus Biopharma Corp | Geliştirilmiş lipit formulasyonu. |
| US8569256B2 (en) | 2009-07-01 | 2013-10-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
| US8283333B2 (en) | 2009-07-01 | 2012-10-09 | Protiva Biotherapeutics, Inc. | Lipid formulations for nucleic acid delivery |
| US9937128B2 (en) * | 2009-08-03 | 2018-04-10 | The University Of North Carolina At Chapel Hill | Liposomes comprising a calcium phosphate-containing precipitate |
| EP2281579A1 (en) | 2009-08-05 | 2011-02-09 | BioNTech AG | Vaccine composition comprising 5'-Cap modified RNA |
| US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
| CN107028886A (zh) | 2009-11-04 | 2017-08-11 | 不列颠哥伦比亚大学 | 含有核酸的脂质粒子及相关的方法 |
| WO2011062965A2 (en) | 2009-11-18 | 2011-05-26 | University Of Washington Through Its Center For Commercialization | Targeting monomers and polymers having targeting blocks |
| PL3338765T3 (pl) | 2009-12-01 | 2019-06-28 | Translate Bio, Inc. | Pochodna steroidowa dla dostarczania mrna w ludzkich chorobach genetycznych |
| KR101878502B1 (ko) | 2009-12-07 | 2018-07-13 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 세포 리프로그래밍을 위한 정제된 변형 ｒｎａ를 포함하는 ｒｎａ 제제 |
| WO2011071860A2 (en) | 2009-12-07 | 2011-06-16 | Alnylam Pharmaceuticals, Inc. | Compositions for nucleic acid delivery |
| WO2011069529A1 (en) | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids |
| TR201906255T4 (tr) | 2009-12-11 | 2019-05-21 | Pfizer | Terapötik partiküllerin liyofilize edilmesine yönelik stabil formülasyonlar. |
| US20110144544A1 (en) | 2009-12-15 | 2011-06-16 | General Electric Company | Ultrasound transducer assembly and methods of using |
| EP3494963A1 (en) | 2009-12-18 | 2019-06-12 | The University of British Columbia | Methods and compositions for delivery of nucleic acids |
| AU2010334911A1 (en) | 2009-12-23 | 2012-07-12 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
| WO2011076142A1 (en) | 2009-12-24 | 2011-06-30 | Fudan University | Compositions and methods for microrna expession profiling in plasma of colorectal cancer |
| WO2011076143A1 (en) | 2009-12-24 | 2011-06-30 | Fudan University | Compositions and methods for microrna expression profiling of lung cancer |
| EP2341145A1 (en) | 2009-12-30 | 2011-07-06 | febit holding GmbH | miRNA fingerprint in the diagnosis of diseases |
| WO2011094683A2 (en) | 2010-01-29 | 2011-08-04 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Method of identifying myelodysplastic syndromes |
| EP2354246A1 (en) | 2010-02-05 | 2011-08-10 | febit holding GmbH | miRNA in the diagnosis of ovarian cancer |
| WO2011113030A2 (en) | 2010-03-11 | 2011-09-15 | H.Lee Moffitt Cancer Center & Research Institute | Human cancer micro-rna expression profiles predictive of chemo-response |
| US9149432B2 (en) | 2010-03-19 | 2015-10-06 | Massachusetts Institute Of Technology | Lipid vesicle compositions and methods of use |
| WO2011119058A2 (en) * | 2010-03-22 | 2011-09-29 | Universidade De Coimbra | F3-peptide targeted lipid-based nanoparticles useful for the treatment of angiogenesis-dependent diseases |
| EP2553019A1 (en) | 2010-03-26 | 2013-02-06 | Mersana Therapeutics, Inc. | Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof |
| WO2011127255A1 (en) | 2010-04-08 | 2011-10-13 | Merck Sharp & Dohme Corp. | Preparation of lipid nanoparticles |
| US8981044B2 (en) * | 2010-04-21 | 2015-03-17 | National University Corporation Hokkaido University | Lipid membrane structure having intranuclear migrating property |
| US20130156845A1 (en) | 2010-04-29 | 2013-06-20 | Alnylam Pharmaceuticals, Inc. | Lipid formulated single stranded rna |
| WO2011143230A1 (en) | 2010-05-10 | 2011-11-17 | Alnylam Pharmaceuticals | Methods and compositions for delivery of active agents |
| US20130123338A1 (en) | 2010-05-12 | 2013-05-16 | Protiva Biotherapeutics, Inc. | Novel cationic lipids and methods of use thereof |
| US10077232B2 (en) | 2010-05-12 | 2018-09-18 | Arbutus Biopharma Corporation | Cyclic cationic lipids and methods of use |
| EP2387999A1 (en) | 2010-05-21 | 2011-11-23 | CureVac GmbH | Histidine-containing solution for transfection and/or injection of nucleic acids and uses thereof |
| US8802863B2 (en) | 2010-05-24 | 2014-08-12 | Sirna Therapeutics, Inc. | Amino alcohol cationic lipids for oligonucleotide delivery |
| US8748667B2 (en) | 2010-06-04 | 2014-06-10 | Sirna Therapeutics, Inc. | Low molecular weight cationic lipids for oligonucleotide delivery |
| WO2011157294A1 (en) | 2010-06-16 | 2011-12-22 | Universita' Degli Studi Di Padova | Compositions for use in treating or preventing cancer, breast cancer, lung cancer, ovarian cancer, metastasis, heart failure, cardiac remodelling, dilated cardiomyopathy, autoimmune diseases, or diseases or disorders related thereto |
| US20130236968A1 (en) | 2010-06-21 | 2013-09-12 | Alnylam Pharmaceuticals, Inc. | Multifunctional copolymers for nucleic acid delivery |
| US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
| US11291635B2 (en) | 2010-07-06 | 2022-04-05 | Glaxosmithkline Biological Sa | Virion-like delivery particles for self-replicating RNA molecules |
| AU2011276234B2 (en) | 2010-07-06 | 2016-02-25 | Glaxosmithkline Biologicals S.A. | Liposomes with lipids having an advantageous pKa- value for RNA delivery |
| US20130230884A1 (en) | 2010-07-16 | 2013-09-05 | John Chaput | Methods to Identify Synthetic and Natural RNA Elements that Enhance Protein Translation |
| US8968746B2 (en) | 2010-07-30 | 2015-03-03 | Curevac Gmbh | Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
| BR112013004879A2 (pt) | 2010-08-31 | 2018-04-24 | Novartis Ag | lipossomas pequenos para entrega de rna que codifica imunogénio |
| WO2012031043A1 (en) | 2010-08-31 | 2012-03-08 | Novartis Ag | Pegylated liposomes for delivery of immunogen-encoding rna |
| TR201908635T4 (tr) | 2010-08-31 | 2019-07-22 | Glaxosmithkline Biologicals Sa | Protein kodlayıcı rna?nın lipozomal verilmesine uygun lipitler. |
| WO2012039979A2 (en) | 2010-09-10 | 2012-03-29 | The Johns Hopkins University | Rapid diffusion of large polymeric nanoparticles in the mammalian brain |
| US8466122B2 (en) | 2010-09-17 | 2013-06-18 | Protiva Biotherapeutics, Inc. | Trialkyl cationic lipids and methods of use thereof |
| MX349088B (es) | 2010-09-20 | 2017-07-10 | Merck Sharp & Dohme | Lípidos catiónicos novedosos de bajo peso molecular para la entrega de oligonucleótidos. |
| KR20130114115A (ko) | 2010-09-30 | 2013-10-16 | 머크 샤프 앤드 돔 코포레이션 | 올리고뉴클레오티드 전달을 위한 저분자량 양이온성 지질 |
| ES3005233T3 (en) | 2010-10-01 | 2025-03-14 | Modernatx Inc | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| CN103153347A (zh) | 2010-10-21 | 2013-06-12 | 默沙东公司 | 用于寡核苷酸递送的新型低分子量阳离子脂质 |
| WO2012089225A1 (en) | 2010-12-29 | 2012-07-05 | Curevac Gmbh | Combination of vaccination and inhibition of mhc class i restricted antigen presentation |
| CA2862765A1 (en) | 2011-01-04 | 2012-07-12 | Brown University | Nanotubes as carriers of nucleic acids into cells |
| JP5902197B2 (ja) | 2011-01-11 | 2016-04-13 | アルニラム・ファーマシューティカルズ・インコーポレーテッド | Ｐｅｇ化脂質および薬剤送達のためのそれらの使用 |
| CN102068701B (zh) | 2011-01-18 | 2012-11-07 | 沈阳药科大学 | 可断裂peg脂质衍生物在制剂中的应用 |
| US10363309B2 (en) | 2011-02-04 | 2019-07-30 | Case Western Reserve University | Targeted nanoparticle conjugates |
| WO2012116715A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in newborns and infants |
| WO2012112730A2 (en) | 2011-02-15 | 2012-08-23 | Merrimack Pharmaceuticals, Inc. | Compositions and methods for delivering nucleic acid to a cell |
| WO2012113413A1 (en) | 2011-02-21 | 2012-08-30 | Curevac Gmbh | Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates |
| WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
| CN102204920B (zh) | 2011-03-18 | 2013-03-20 | 海南本创医药科技有限公司 | 阿司匹林钠普伐他汀钠药物组合物固体制剂 |
| US10357568B2 (en) | 2011-03-24 | 2019-07-23 | Glaxosmithkline Biologicals S.A. | Adjuvant nanoemulsions with phospholipids |
| US9238716B2 (en) | 2011-03-28 | 2016-01-19 | Massachusetts Institute Of Technology | Conjugated lipomers and uses thereof |
| JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
| WO2013158127A1 (en) | 2012-04-16 | 2013-10-24 | Molecular Transfer, Inc. | Agents for improved delivery of nucleic acids to eukaryotic cells |
| EP2701686A4 (en) | 2011-04-28 | 2014-11-05 | Stc Unm | LIPID BINCHES SUPPORTED ON POROUS NANOPARTICLES (PROTOCELLS) FOR TARGETED ADMINISTRATION, AND METHODS OF USE THEREOF |
| CN103635179B (zh) | 2011-04-28 | 2017-12-29 | 普拉福姆五金器具第二有限公司 | 亲脂性药剂的改进的胃肠外制剂以及制备和使用其的方法 |
| KR20140041505A (ko) | 2011-04-29 | 2014-04-04 | 셀렉타 바이오사이언시즈, 인크. | 조절 b 세포 유도를 위한 관용원성 합성 나노운반체 |
| WO2012151212A1 (en) | 2011-05-01 | 2012-11-08 | University Of Rochester | Multifocal hepatocellular carcinoma microrna expression patterns and uses thereof |
| CA2835179A1 (en) | 2011-05-06 | 2012-11-15 | Xentech | Markers for cancer prognosis and therapy and methods of use |
| US9283279B2 (en) | 2011-05-11 | 2016-03-15 | Ramot At Tel-Aviv University Ltd. | Targeted polymeric conjugates and uses thereof |
| EP2706983A1 (en) | 2011-05-12 | 2014-03-19 | Helmut Vockner | Novel pharmaceutical formulation |
| DK2706988T3 (da) | 2011-05-12 | 2020-01-20 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Liposomer omfattende polymer konjugerede lipider og relateret brug |
| CN103687957A (zh) | 2011-05-17 | 2014-03-26 | 现代治疗公司 | 工程化核酸及其用于非人类脊椎动物的方法 |
| US8691750B2 (en) | 2011-05-17 | 2014-04-08 | Axolabs Gmbh | Lipids and compositions for intracellular delivery of biologically active compounds |
| WO2012159643A1 (en) | 2011-05-24 | 2012-11-29 | Biontech Ag | Individualized vaccines for cancer |
| US20140094461A1 (en) | 2011-06-02 | 2014-04-03 | Novartis Ag | Biomarkers for hedgehog inhibitor therapy |
| CN107115314B (zh) | 2011-06-02 | 2022-04-29 | 加利福尼亚大学董事会 | 膜包封的纳米颗粒及使用方法 |
| PT2717893T (pt) | 2011-06-08 | 2019-08-20 | Translate Bio Inc | Composições de nanopartículas lipídicas e métodos para transferência de arnm |
| DK3336082T3 (da) | 2011-06-08 | 2020-04-27 | Translate Bio Inc | Spaltelige lipider |
| KR102029654B1 (ko) | 2011-06-08 | 2019-10-08 | 닛토덴코 가부시키가이샤 | 표적 약물 전달체 및 ｓｉＲＮＡ 활성을 증가시키는 화합물 |
| CN102813929B (zh) | 2011-06-09 | 2014-04-09 | 沈阳药科大学 | 低浓度peg脂质衍生物及其应用 |
| WO2012168491A1 (en) | 2011-06-10 | 2012-12-13 | Novartis Ag | Pharmaceutical formulations of pcsk9 antagonists |
| WO2012170607A2 (en) | 2011-06-10 | 2012-12-13 | Novartis Ag | Use of pcsk9 antagonists |
| EP4014966A1 (en) | 2011-07-06 | 2022-06-22 | GlaxoSmithKline Biologicals S.A. | Liposomes having useful n:p ratio for delivery of rna molecules |
| EP3854413A1 (en) | 2011-07-06 | 2021-07-28 | GlaxoSmithKline Biologicals SA | Immunogenic combination compositions and uses thereof |
| CA2841047A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic compositions and uses thereof |
| AU2012280901B2 (en) | 2011-07-06 | 2016-11-10 | Glaxosmithkline Biologicals S.A. | Oil-in-water emulsions that contain nucleic acids |
| RU2649133C2 (ru) | 2011-07-06 | 2018-03-29 | Новартис Аг | Катионные эмульсии масло-в-воде |
| WO2013011378A1 (en) | 2011-07-15 | 2013-01-24 | Leo Pharma A/S | Diagnostic microrna profiling in cutaneous t-cell lymphoma (ctcl) |
| JP6018197B2 (ja) | 2011-07-21 | 2016-11-02 | クローダ インターナショナル パブリック リミティド カンパニー | 分枝状ポリエーテル−ポリアミドブロックコポリマー並びにそれらの製造方法及び使用方法 |
| KR20140051357A (ko) | 2011-08-26 | 2014-04-30 | 애로우헤드 리서치 코오포레이션 | Ｉｎ Ｖｉｖｏ 핵산 전달용 폴리(비닐 에스테르) 고분자 |
| US9126966B2 (en) | 2011-08-31 | 2015-09-08 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use thereof |
| SG11201400250UA (en) * | 2011-08-31 | 2014-03-28 | Novartis Ag | Pegylated liposomes for delivery of immunogen-encoding rna |
| US8889657B2 (en) | 2011-08-31 | 2014-11-18 | Mallinckrodt Llc | Nanoparticle PEG modification with H-phosphonates |
| WO2013033640A1 (en) | 2011-09-01 | 2013-03-07 | Allegro Diagnostics Corp. | Methods and compositions for detecting cancer based on mirna expression profiles |
| JP2014525462A (ja) | 2011-09-01 | 2014-09-29 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Ｐｄｇｆｒキナーゼ阻害剤としての化合物および組成物 |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| WO2013039861A2 (en) | 2011-09-12 | 2013-03-21 | modeRNA Therapeutics | Engineered nucleic acids and methods of use thereof |
| US9375388B2 (en) | 2011-09-23 | 2016-06-28 | Indian Institute Of Technology, Bombay | Nanoparticle based cosmetic composition |
| EP2760477B1 (en) | 2011-09-27 | 2018-08-08 | Alnylam Pharmaceuticals, Inc. | Di-aliphatic substituted pegylated lipids |
| AU2012323937A1 (en) | 2011-10-14 | 2014-06-05 | Stc.Unm | Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof |
| ES2745373T3 (es) | 2011-10-18 | 2020-03-02 | Dicerna Pharmaceuticals Inc | Lípidos catiónicos de amina y uso de los mismos |
| US20140248320A1 (en) | 2011-10-20 | 2014-09-04 | Novartis Ag | Adjuvanted influenza b virus vaccines for pediatric priming |
| US20140328759A1 (en) | 2011-10-25 | 2014-11-06 | The University Of British Columbia | Limit size lipid nanoparticles and related methods |
| WO2013066678A1 (en) | 2011-10-26 | 2013-05-10 | Georgetown University | Microrna expression profiling of thyroid cancer |
| KR20150000461A (ko) | 2011-10-27 | 2015-01-02 | 메사추세츠 인스티튜트 오브 테크놀로지 | 약물 캡슐화 마이크로스피어를 형성할 수 있는, ｎ-말단 상에 관능화된 아미노산 유도체 |
| WO2013066903A1 (en) | 2011-10-31 | 2013-05-10 | Mallinckrodt Llc | Combinational liposome compositions for cancer therapy |
| ES2721325T3 (es) | 2011-11-04 | 2019-07-31 | Nitto Denko Corp | Método para producir de manera estéril partículas de lípido-ácido nucleico |
| WO2013066274A1 (en) | 2011-11-04 | 2013-05-10 | Agency For Science, Technology And Research | Self-assembled composite ultrasmall peptide-polymer hydrogels |
| US9872870B2 (en) | 2011-11-04 | 2018-01-23 | University Of Notre Dame Du Lac | Multifunctional micellar nanoparticle-based drug and targeting agent system |
| US9579338B2 (en) | 2011-11-04 | 2017-02-28 | Nitto Denko Corporation | Method of producing lipid nanoparticles for drug delivery |
| US9849087B2 (en) | 2011-11-08 | 2017-12-26 | The Board Of Trustees Of The University Of Arkansas | Methods and compositions for X-ray induced release from pH sensitive liposomes |
| WO2013082529A1 (en) | 2011-12-02 | 2013-06-06 | Yale University | Enzymatic synthesis of poly(amine-co-esters) and methods of use thereof for gene delivery |
| WO2013086373A1 (en) | 2011-12-07 | 2013-06-13 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
| ES3065854T3 (en) | 2011-12-07 | 2026-05-08 | Alnylam Pharmaceuticals Inc | Biodegradable lipids for the delivery of active agents |
| US9463247B2 (en) | 2011-12-07 | 2016-10-11 | Alnylam Pharmaceuticals, Inc. | Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents |
| WO2013086526A1 (en) | 2011-12-09 | 2013-06-13 | The Regents Of The University Of California | Liposomal drug encapsulation |
| AU2012353463B2 (en) | 2011-12-12 | 2017-08-24 | Kyowa Hakko Kirin Co., Ltd. | Lipid nanoparticles containing combinations of cationic lipids |
| JP6182457B2 (ja) | 2011-12-12 | 2017-08-16 | 協和発酵キリン株式会社 | カチオン性脂質を含有するドラックデリバリーシステムのための脂質ナノ粒子 |
| EP2604253A1 (en) | 2011-12-13 | 2013-06-19 | Otto Glatter | Water-in-oil emulsions and methods for their preparation |
| WO2013130161A1 (en) | 2011-12-14 | 2013-09-06 | modeRNA Therapeutics | Methods of responding to a biothreat |
| WO2013087083A1 (en) | 2011-12-15 | 2013-06-20 | Biontech Ag | Particles comprising single stranded rna and double stranded rna for immunomodulation |
| WO2013090601A2 (en) | 2011-12-16 | 2013-06-20 | Massachusetts Institute Of Technology | Compact nanoparticles for biological applications |
| JP2015501844A (ja) | 2011-12-16 | 2015-01-19 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物 |
| CN104968354A (zh) | 2011-12-21 | 2015-10-07 | 现代治疗公司 | 增加器官或器官外植体的活力或寿命的方法 |
| EP4721752A2 (en) | 2011-12-30 | 2026-04-08 | Cellscript, Llc | Herstellung und verwendung von in vitro-synthetisierter ssrna zur einführung in säugetierzellen zur induktion einer biologischen oder biochemischen wirkung |
| WO2013103659A1 (en) | 2012-01-04 | 2013-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Stabilizing rna by incorporating chain-terminating nucleosides at the 3'-terminus |
| AU2013212066B2 (en) | 2012-01-26 | 2018-11-08 | Life Technologies Corporation | Methods for increasing the infectivity of viruses |
| SG11201404361UA (en) | 2012-01-26 | 2014-09-26 | Life Technologies Corp | Methods for increasing the infectivity of viruses |
| WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
| EP2623121A1 (en) | 2012-01-31 | 2013-08-07 | Bayer Innovation GmbH | Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen |
| WO2013113325A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Negatively charged nucleic acid comprising complexes for immunostimulation |
| WO2013120500A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen |
| WO2013120499A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen |
| WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
| WO2013120498A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen |
| US20140037573A1 (en) | 2012-02-22 | 2014-02-06 | Cerulean Pharma Inc. | Conjugates, particles, compositions, and related methods |
| DK2817287T3 (da) | 2012-02-24 | 2019-01-02 | Arbutus Biopharma Corp | Trialkyl kationisk lipid og metoder til anvendelse deraf |
| US10322089B2 (en) | 2012-03-14 | 2019-06-18 | The Board Of Trustees Of The Leland Stanford Junior University | Nanoparticles, nanoparticle delivery methods, and systems of delivery |
| NZ631034A (en) | 2012-03-16 | 2016-06-24 | Merck Patent Gmbh | Targeting aminoacid lipids |
| AU2013232297B2 (en) | 2012-03-16 | 2016-01-14 | The Johns Hopkins University | Controlled release formulations for the delivery of HIF-1 inhibitors |
| EP2825207B1 (en) | 2012-03-16 | 2020-08-19 | The Johns Hopkins University | Non-linear multiblock copolymer-drug conjugates for the delivery of active agents |
| WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| EP2830991A1 (en) | 2012-03-26 | 2015-02-04 | President and Fellows of Harvard College | Lipid-coated nucleic acid nanostructures of defined shape |
| SG11201405545XA (en) | 2012-03-27 | 2014-11-27 | Curevac Gmbh | Artificial nucleic acid molecules comprising a 5'top utr |
| MX357803B (es) | 2012-03-27 | 2018-07-24 | Curevac Ag | Moléculas de ácido nucleico artificiales. |
| CA2867323C (en) | 2012-03-27 | 2020-07-07 | Sirna Therapeutics, Inc. | Diether based biodegradable cationic lipids for sirna delivery |
| CA2859452C (en) | 2012-03-27 | 2021-12-21 | Curevac Gmbh | Artificial nucleic acid molecules for improved protein or peptide expression |
| EP3865123A1 (en) | 2012-03-29 | 2021-08-18 | Translate Bio, Inc. | Lipid-derived neutral nanoparticles |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| US10501513B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides for the production of oncology-related proteins and peptides |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| CN108949772A (zh) | 2012-04-02 | 2018-12-07 | 现代泰克斯公司 | 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸 |
| WO2013151663A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of membrane proteins |
| WO2013151650A1 (en) | 2012-04-05 | 2013-10-10 | University Of Florida Research Foundation, Inc. | Neurophilic nanoparticles |
| CA2870182A1 (en) | 2012-04-10 | 2013-10-17 | The Trustees Of The University Of Pennsylvania | Human respiratory syncytial virus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same |
| ES2560235T3 (es) | 2012-04-11 | 2016-02-18 | Intezyne Technologies Inc. | Copolímeros en bloque para micelas estables |
| WO2013155487A1 (en) | 2012-04-12 | 2013-10-17 | Yale University | Vehicles for controlled delivery of different pharmaceutical agents |
| US9402816B2 (en) | 2012-04-19 | 2016-08-02 | Sima Therapeutics, Inc. | Diester and triester based low molecular weight, biodegradeable cationic lipids for oligonucleotide delivery |
| CA2872519C (en) | 2012-05-04 | 2017-09-05 | The Johns Hopkins University | Lipid-based drug carriers for rapid penetration through mucus linings |
| WO2013173693A1 (en) | 2012-05-18 | 2013-11-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nanoparticles with enhanced entry into cancer cells |
| AU2013266238B2 (en) | 2012-05-23 | 2017-07-27 | The Ohio State University | Lipid-coated albumin nanoparticle compositions and methods of making and method of using the same |
| ES2719598T3 (es) | 2012-05-25 | 2019-07-11 | Curevac Ag | Inmovilización reversible y/o liberación controlada de ácidos nucleicos contenidos en nanopartículas mediante revestimientos poliméricos (biodegradables) |
| EP2858974B9 (en) | 2012-06-08 | 2022-07-20 | Nitto Denko Corporation | Lipids for therapeutic agent delivery formulations |
| WO2013185069A1 (en) | 2012-06-08 | 2013-12-12 | Shire Human Genetic Therapies, Inc. | Pulmonary delivery of mrna to non-lung target cells |
| US9415109B2 (en) | 2012-07-06 | 2016-08-16 | Alnylam Pharmaceuticals, Inc. | Stable non-aggregating nucleic acid lipid particle formulations |
| US9931418B2 (en) | 2012-08-07 | 2018-04-03 | Northeastern University | Compositions for the delivery of RNA and drugs into cells |
| WO2014024193A1 (en) | 2012-08-07 | 2014-02-13 | Prodel Pharma Ltd. | Compositions and methods for rapid transmucosal delivery of pharmaceutical ingredients |
| EP2882706A1 (en) * | 2012-08-13 | 2015-06-17 | Massachusetts Institute of Technology | Amine-containing lipidoids and uses thereof |
| WO2014028429A2 (en) | 2012-08-14 | 2014-02-20 | Moderna Therapeutics, Inc. | Enzymes and polymerases for the synthesis of rna |
| CA2881605A1 (en) | 2012-08-14 | 2014-02-20 | Aaron FROESE | Internal structured self assembling liposomes |
| WO2014028763A1 (en) | 2012-08-15 | 2014-02-20 | The University Of Chicago | Exosome-based therapeutics against neurodegenerative disorders |
| US8703197B2 (en) | 2012-09-13 | 2014-04-22 | International Business Machines Corporation | Branched polyamines for delivery of biologically active materials |
| EP2895156B1 (en) | 2012-09-17 | 2019-05-08 | Pfizer Inc. | Process for preparing therapeutic nanoparticles |
| WO2014047649A1 (en) | 2012-09-24 | 2014-03-27 | The Regents Of The University Of California | Methods for arranging and packing nucleic acids for unusual resistance to nucleases and targeted delivery for gene therapy |
| US20150246137A1 (en) | 2012-09-27 | 2015-09-03 | The University Of North Carolina At Chapel Hill | Lipid coated nanoparticles containing agents having low aqueous and lipid solubilities and methods thereof |
| WO2014053882A1 (en) | 2012-10-04 | 2014-04-10 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| CN104812372A (zh) | 2012-10-04 | 2015-07-29 | 约翰内斯堡金山大学 | 脂质体药物递送系统 |
| WO2014053881A1 (en) | 2012-10-04 | 2014-04-10 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| WO2014053879A1 (en) | 2012-10-04 | 2014-04-10 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| WO2014053880A1 (en) | 2012-10-04 | 2014-04-10 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| JP2015536323A (ja) | 2012-10-16 | 2015-12-21 | エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． | 非天然アミノ酸を含む薬物送達結合体および使用方法 |
| AU2013336237A1 (en) | 2012-10-22 | 2015-06-11 | Sabag-Rfa Ltd | A system for delivering therapeutic agents into living cells and cells nuclei |
| WO2014066898A1 (en) | 2012-10-26 | 2014-05-01 | The Johns Hopkins University | A layer-by-layer approach to co-deliver dna and sirna via aunps: a potential platform for modifying release kinetics |
| EP2911697A1 (en) | 2012-10-26 | 2015-09-02 | Nlife Therapeutics S.L. | Compositions and methods for selective delivery of oligonucleotide molecules to cell types |
| WO2014071072A2 (en) | 2012-11-02 | 2014-05-08 | Pungente Michael D | Novel cationic carotenoid-based lipids for cellular nucleic acid uptake |
| NZ707855A (en) | 2012-11-06 | 2018-11-30 | Rochal Ind Llc | Delivery of biologically-active agents using volatile, hydrophobic solvents |
| US9669104B2 (en) | 2012-11-07 | 2017-06-06 | Council Of Scientific And Industrial Research | Nanocomplex containing amphipathic peptide useful for efficient transfection of biomolecules |
| KR102467714B1 (ko) | 2012-11-08 | 2022-11-16 | 클리어사이드 바이오메디컬, 인코포레이드 | 인간 대상체에서 안구 질병을 치료하기 위한 방법 및 장치 |
| WO2014072468A1 (en) | 2012-11-09 | 2014-05-15 | Velin-Pharma A/S | Compositions for pulmonary delivery |
| US9200119B2 (en) | 2012-11-09 | 2015-12-01 | Momentive Performance Materials Inc. | Silicon-containing zwitterionic linear copolymer composition |
| WO2014074218A1 (en) | 2012-11-12 | 2014-05-15 | Redwood Bioscience, Inc. | Compounds and methods for producing a conjugate |
| US9943608B2 (en) | 2012-11-13 | 2018-04-17 | Baylor College Of Medicine | Multi-arm biodegradable polymers for nucleic acid delivery |
| EP2732825B1 (en) | 2012-11-19 | 2015-07-01 | Invivogen | Conjugates of a TLR7 and/or TLR8 agonist and a TLR2 agonist |
| US20150290328A1 (en) | 2012-11-20 | 2015-10-15 | Phasebio Pharmaceuticals, Inc. | Formulations of active agents for sustained release |
| WO2014081300A1 (en) | 2012-11-22 | 2014-05-30 | Tagworks Pharmaceuticals B.V. | Channel protein activatable liposomes |
| EP2922574B1 (en) | 2012-11-22 | 2023-05-17 | Tagworks Pharmaceuticals B.V. | Chemically cleavable group |
| WO2014081299A1 (en) | 2012-11-22 | 2014-05-30 | Tagworks Pharmaceuticals B.V. | Activatable liposomes |
| ES2921623T3 (es) | 2012-11-26 | 2022-08-30 | Modernatx Inc | ARN modificado terminalmente |
| US9687448B2 (en) | 2012-12-07 | 2017-06-27 | Alnylam Pharmaceuticals, Inc. | Nucleic acid lipid particle formulations |
| EP2929035A1 (en) | 2012-12-07 | 2015-10-14 | Shire Human Genetic Therapies, Inc. | Lipidic nanoparticles for mrna delivering |
| EP2931319B1 (en) | 2012-12-13 | 2019-08-21 | ModernaTX, Inc. | Modified nucleic acid molecules and uses thereof |
| US20150315541A1 (en) | 2012-12-13 | 2015-11-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for altering cell phenotype |
| WO2014108515A1 (en) | 2013-01-10 | 2014-07-17 | Novartis Ag | Influenza virus immunogenic compositions and uses thereof |
| JP2016504050A (ja) | 2013-01-17 | 2016-02-12 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 細胞表現型の改変のためのシグナルセンサーポリヌクレオチド |
| WO2014127917A1 (en) | 2013-02-22 | 2014-08-28 | Curevac Gmbh | Combination of vaccination and inhibition of the pd-1 pathway |
| US20160024181A1 (en) | 2013-03-13 | 2016-01-28 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
| US20160032316A1 (en) | 2013-03-14 | 2016-02-04 | The Trustees Of The University Of Pennsylvania | Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides |
| EP2968149B1 (en) | 2013-03-14 | 2024-05-08 | Dicerna Pharmaceuticals, Inc. | Process for formulating an anionic agent |
| ES2981185T3 (es) | 2013-03-14 | 2024-10-07 | Translate Bio Inc | Métodos para la purificación de ARN mensajero |
| US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| EP2983804A4 (en) | 2013-03-15 | 2017-03-01 | Moderna Therapeutics, Inc. | Ion exchange purification of mrna |
| EP2971033B8 (en) | 2013-03-15 | 2019-07-10 | ModernaTX, Inc. | Manufacturing methods for production of rna transcripts |
| WO2014144039A1 (en) | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Characterization of mrna molecules |
| US9693958B2 (en) | 2013-03-15 | 2017-07-04 | Cureport, Inc. | Methods and devices for preparation of lipid nanoparticles |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US11155572B2 (en) | 2013-03-15 | 2021-10-26 | Glaxosmithkline Biologicals Sa | RNA purification methods |
| EP2971161B1 (en) | 2013-03-15 | 2018-12-26 | ModernaTX, Inc. | Ribonucleic acid purification |
| EP4614148A3 (en) | 2013-03-15 | 2025-12-17 | Translate Bio, Inc. | Synergistic enhancement of the delivery of nucleic acids via blended formulations |
| WO2014165782A2 (en) * | 2013-04-05 | 2014-10-09 | Massachusetts Institute Of Technology | Compositions, methods, and kits comprising platinum compounds associated with a ligand comprising a targeting moiety |
| BR112015025460B1 (pt) | 2013-04-07 | 2024-01-02 | The Broad Institute, Inc. | Método para a produção de uma vacina personalizada contra a neoplasia para um indivíduo diagnosticado como tendo uma neoplasia, vacina personalizada e uso da mesma |
| TW201515650A (zh) | 2013-05-06 | 2015-05-01 | 艾爾妮蘭製藥公司 | 遞送經脂質調配之核酸分子之劑量及方法 |
| US9895443B2 (en) | 2013-06-26 | 2018-02-20 | Massachusetts Institute Of Technology | Multi-tailed lipids and uses thereof |
| WO2015002667A1 (en) | 2013-07-01 | 2015-01-08 | Myq, Inc. | A location regulated point-of-sale system and enhancements |
| TW201534578A (zh) | 2013-07-08 | 2015-09-16 | Daiichi Sankyo Co Ltd | 新穎脂質 |
| HUE056760T2 (hu) | 2013-07-11 | 2022-03-28 | Modernatx Inc | A CRISPR-hez kapcsolódó fehérjéket és a szintetikus SGRNS-ket kódoló szintetikus polinukleotidokat tartalmazó készítmények és felhasználási módjaik |
| WO2015011633A1 (en) | 2013-07-23 | 2015-01-29 | Protiva Biotherapeutics, Inc. | Compositions and methods for delivering messenger rna |
| US10125172B2 (en) | 2013-07-25 | 2018-11-13 | Calder Biosciences Inc. | Conformationally stabilized RSV pre-fusion F proteins |
| US10398769B2 (en) | 2013-08-06 | 2019-09-03 | The Trustees Of The University Of Pennsylvania | Influenza nucleic acid molecules and vaccines made therefrom |
| CN105517566A (zh) | 2013-08-21 | 2016-04-20 | 库瑞瓦格股份公司 | 用于治疗前列腺癌的组合物和疫苗 |
| CN105517569A (zh) | 2013-08-21 | 2016-04-20 | 库瑞瓦格股份公司 | 狂犬病疫苗 |
| AU2014310933B2 (en) | 2013-08-21 | 2020-05-14 | CureVac SE | Method for increasing expression of RNA-encoded proteins |
| WO2015024669A1 (en) | 2013-08-21 | 2015-02-26 | Curevac Gmbh | Combination vaccine |
| JP6678582B2 (ja) | 2013-08-21 | 2020-04-08 | キュアバック アーゲー | 肺癌処置のための組成物およびワクチン、組み合わせ、キット |
| CA2915728A1 (en) | 2013-08-21 | 2015-02-26 | Thomas Kramps | Respiratory syncytial virus (rsv) vaccine |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| WO2015051169A2 (en) | 2013-10-02 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotide molecules and uses thereof |
| KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
| US20160243221A1 (en) | 2013-10-18 | 2016-08-25 | Moderna Therapeutics, Inc. | Compositions and methods for tolerizing cellular systems |
| CA2928040A1 (en) | 2013-10-22 | 2015-04-30 | Shire Human Genetic Therapies, Inc. | Cns delivery of mrna and uses thereof |
| ES2806575T3 (es) | 2013-11-01 | 2021-02-18 | Curevac Ag | ARN modificado con propiedades inmunoestimuladoras disminuidas |
| EP3082760A1 (en) | 2013-12-19 | 2016-10-26 | Novartis AG | LEPTIN mRNA COMPOSITIONS AND FORMULATIONS |
| WO2015095346A1 (en) | 2013-12-19 | 2015-06-25 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| PT3083556T (pt) * | 2013-12-19 | 2020-03-05 | Novartis Ag | Lípidos e composições lipídicas para a entrega de agentes ativos |
| CN111304231A (zh) | 2013-12-30 | 2020-06-19 | 库瑞瓦格股份公司 | 人工核酸分子 |
| WO2015101415A1 (en) | 2013-12-30 | 2015-07-09 | Curevac Gmbh | Artificial nucleic acid molecules |
| AU2014375404C1 (en) | 2013-12-30 | 2020-11-19 | CureVac Manufacturing GmbH | Methods for RNA analysis |
| EP3791863B1 (en) | 2014-01-21 | 2025-09-10 | Anjarium Biosciences AG | Process for the production of hybridosomes |
| WO2015130584A2 (en) | 2014-02-25 | 2015-09-03 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
| MX369776B (es) | 2014-03-01 | 2019-11-21 | Univ Texas | Vectores recombinantes del virus isfahan. |
| ES2754239T3 (es) | 2014-03-12 | 2020-04-16 | Curevac Ag | Combinación de vacunación y agonistas de OX40 |
| DK3134131T3 (en) | 2014-04-23 | 2022-02-07 | Modernatx Inc | Nucleic acid vaccines |
| WO2015196128A2 (en) | 2014-06-19 | 2015-12-23 | Moderna Therapeutics, Inc. | Alternative nucleic acid molecules and uses thereof |
| IL316479A (en) | 2014-06-25 | 2024-12-01 | Acuitas Therapeutics Inc | Novel lipids and lipid nanoparticle compositions for nucleic acid delivery |
| EP3169693B1 (en) | 2014-07-16 | 2022-03-09 | ModernaTX, Inc. | Chimeric polynucleotides |
| EP3169783A4 (en) | 2014-07-17 | 2018-10-03 | Modernatx, Inc. | Terminal modifications of polynucleotides |
| CN107072946B (zh) | 2014-09-05 | 2022-01-11 | 诺华股份有限公司 | 用于递送活性剂的脂质和脂质组合物 |
| CN104644555A (zh) | 2014-11-18 | 2015-05-27 | 中国科学院过程工程研究所 | 一种避免加速血液清除现象的长循环脂质体、制备方法及应用 |
| WO2016118724A1 (en) | 2015-01-21 | 2016-07-28 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
| EP3253373B1 (en) | 2015-02-08 | 2020-03-18 | Tongli Biomedical Co., Ltd. | Lipid nanoparticles and uses thereof |
| WO2016164762A1 (en) | 2015-04-08 | 2016-10-13 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor egf-a and intracellular domain mutants and methods of using the same |
| EP3283059B1 (en) | 2015-04-13 | 2024-01-03 | CureVac Manufacturing GmbH | Method for producing rna compositions |
| EP3307305A4 (en) | 2015-06-10 | 2019-05-22 | Modernatx, Inc. | TARGETED ADAPTIVE VACCINES |
| HUE067372T2 (hu) | 2015-06-29 | 2024-10-28 | Acuitas Therapeutics Inc | Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására |
| WO2017011773A2 (en) | 2015-07-15 | 2017-01-19 | Modernatx, Inc. | Codon-optimized nucleic acids encoding antibodies |
| WO2017015457A1 (en) | 2015-07-21 | 2017-01-26 | Modernatx, Inc. | Ebola vaccine |
| MA42502A (fr) | 2015-07-21 | 2018-05-30 | Modernatx Inc | Vaccins contre une maladie infectieuse |
| WO2017019935A1 (en) | 2015-07-30 | 2017-02-02 | Modernatx, Inc. | Multimeric mrna |
| WO2017020026A1 (en) | 2015-07-30 | 2017-02-02 | Modernatx, Inc. | Concatemeric peptide epitopes rnas |
| WO2017031241A1 (en) | 2015-08-17 | 2017-02-23 | Modernatx, Inc. | Rna mapping/fingerprinting |
| US11564893B2 (en) | 2015-08-17 | 2023-01-31 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| US20170049709A1 (en) | 2015-08-21 | 2017-02-23 | Pfizer Inc. | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same |
| RS63030B1 (sr) | 2015-09-17 | 2022-04-29 | Modernatx Inc | Jedinjenja i kompozicije za intracelularno isporučivanje terapeutskih sredstava |
| EP3359670B2 (en) | 2015-10-05 | 2024-02-14 | ModernaTX, Inc. | Methods for therapeutic administration of messenger ribonucleic acid drugs |
| WO2017066789A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Mrna cap analogs with modified sugar |
| CN108430456B (zh) | 2015-10-22 | 2022-01-18 | 摩登纳特斯有限公司 | 癌症疫苗 |
| EP3364981A4 (en) | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS |
| MD3718565T2 (ro) | 2015-10-22 | 2022-09-30 | Modernatx Inc | Vaccinuri împotriva virusului respirator |
| AU2016342376A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Sexually transmitted disease vaccines |
| WO2017070601A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Nucleic acid vaccines for varicella zoster virus (vzv) |
| EP3365009A4 (en) | 2015-10-22 | 2019-07-03 | ModernaTX, Inc. | VACCINES AGAINST HERPES SIMPLEX VIRUS |
| EP3364950A4 (en) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | VACCINES AGAINST TROPICAL DISEASES |
| AU2016342048B2 (en) | 2015-10-22 | 2022-09-08 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| TN2018000154A1 (en) | 2015-10-22 | 2019-10-04 | Modernatx Inc | Respiratory syncytial virus vaccine |
| US12318489B2 (en) | 2015-10-26 | 2025-06-03 | Translate Bio Ma, Inc. | Nanoparticle formulations for delivery of nucleic acid complexes |
| CA3007955A1 (en) | 2015-12-10 | 2017-06-15 | Modernatx, Inc. | Lipid nanoparticles for delivery of therapeutic agents |
| EP3390630B1 (en) | 2015-12-17 | 2025-01-22 | ModernaTX, Inc. | Polynucleotides encoding methylmalonyl-coa mutase |
| JP7114465B2 (ja) | 2015-12-22 | 2022-08-08 | モデルナティエックス インコーポレイテッド | 薬剤の細胞内送達のための化合物および組成物 |
| US10465190B1 (en) | 2015-12-23 | 2019-11-05 | Modernatx, Inc. | In vitro transcription methods and constructs |
| EP3405579A1 (en) | 2016-01-22 | 2018-11-28 | Modernatx, Inc. | Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof |
| WO2017191274A2 (en) | 2016-05-04 | 2017-11-09 | Curevac Ag | Rna encoding a therapeutic protein |
| EP3458092A1 (en) | 2016-05-18 | 2019-03-27 | Modernatx, Inc. | Mrna combination therapy for the treatment of cancer |
| JP7088911B2 (ja) | 2016-05-18 | 2022-06-21 | モデルナティエックス インコーポレイテッド | リラキシンをコードするポリヌクレオチド |
| US20190298657A1 (en) | 2016-05-18 | 2019-10-03 | Modernatx, Inc. | Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency |
| WO2017201349A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding citrin for the treatment of citrullinemia type 2 |
| MA45032A (fr) | 2016-05-18 | 2019-03-27 | Fundacion Para La Investig Medica Aplicada | Polynucléotides codant pour la porphobilinogène désaminase destinés au traitement de la porphyrie intermittente aiguë |
| MA45053A (fr) | 2016-05-18 | 2019-03-27 | Modernatx Inc | Polynucléotides codant pour un régulateur de conductance transmembranaire de fibrose kystique pour le traitement de la fibrose kystique |
| EP3896164A1 (en) | 2016-05-18 | 2021-10-20 | ModernaTX, Inc. | Polynucleotides encoding alpha-galactosidase a for the treatment of fabry disease |
| US12128113B2 (en) | 2016-05-18 | 2024-10-29 | Modernatx, Inc. | Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome |
| US11001861B2 (en) | 2016-05-18 | 2021-05-11 | Modernatx, Inc. | Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1 |
| US12123030B2 (en) | 2016-05-18 | 2024-10-22 | Modernatx, Inc. | Polynucleotides encoding lipoprotein lipase for the treatment of hyperlipidemia |
| US20190382774A1 (en) | 2016-05-18 | 2019-12-19 | Modernatx, Inc. | Polyribonucleotides containing reduced uracil content and uses thereof |
| WO2017218704A1 (en) | 2016-06-14 | 2017-12-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| WO2017219033A1 (en) | 2016-06-17 | 2017-12-21 | Montana State University | Bidirectional targeting for genome editing |
| AU2017286980B2 (en) | 2016-06-30 | 2023-10-26 | Arbutus Biopharma Corporation | Compositions and methods for delivering messenger RNA |
| MA45999A (fr) * | 2016-08-22 | 2019-06-26 | Arbutus Biopharma Corp | Anticorps anti-pd-1, ou leurs fragments, pour le traitement de l'hépatite b |
| JP6983455B2 (ja) | 2016-09-14 | 2021-12-17 | モデルナティーエックス， インコーポレイテッド | 高純度ｒｎａ組成物及びその調製のための方法 |
| AU2017345766A1 (en) | 2016-10-21 | 2019-05-16 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| WO2018081462A1 (en) | 2016-10-26 | 2018-05-03 | Modernatx, Inc. | Methods and compositions for rna mapping |
| EP3532070A1 (en) | 2016-10-26 | 2019-09-04 | Modernatx, Inc. | Messenger ribonucleic acids for enhancing immune responses and methods of use thereof |
| EP4714454A2 (en) | 2016-10-26 | 2026-03-25 | Acuitas Therapeutics Inc. | Lipid nanoparticle formulations |
| MX2019004913A (es) | 2016-10-26 | 2019-09-16 | Curevac Ag | Vacunas de nanoparticulas lipidicas que comprenden acido ribonucleico mensajero (arnm). |
| US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| MA46762A (fr) | 2016-11-10 | 2019-09-18 | Translate Bio Inc | Procédé amélioré de préparation de nanoparticules lipidiques chargées d'arnm |
| MX2019005470A (es) | 2016-11-10 | 2019-11-21 | Translate Bio Inc | Formulación de nanopartículas lipídicas basadas en ice mejorada para el suministro de arnm. |
| CN110167587A (zh) | 2016-11-11 | 2019-08-23 | 摩登纳特斯有限公司 | 流感疫苗 |
| EP3551193A4 (en) | 2016-12-08 | 2020-08-19 | Modernatx, Inc. | NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES |
| EP3555289A1 (en) | 2016-12-13 | 2019-10-23 | ModernaTX, Inc. | Rna affinity purification |
| WO2018115507A2 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Henipavirus vaccine |
| US20180243225A1 (en) | 2017-01-25 | 2018-08-30 | Modernatx, Inc. | Ebola/marburg vaccines |
| EP3576780A1 (en) | 2017-02-01 | 2019-12-11 | Modernatx, Inc. | Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides |
| RU2768829C2 (ru) | 2017-02-01 | 2022-03-24 | МОДЕРНАТиЭкс, ИНК. | Противораковые рнк-вакцины |
| US20200032274A1 (en) | 2017-02-01 | 2020-01-30 | Moderna TX, Inc. | Polynucleotide secondary structure |
| WO2018151816A1 (en) | 2017-02-16 | 2018-08-23 | Modernatx, Inc. | High potency immunogenic compositions |
| US20200368162A1 (en) | 2017-02-24 | 2020-11-26 | Modernatx, Inc. | Nucleic Acid-Based Therapy of Muscular Dystrophies |
| WO2018170245A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| US11752206B2 (en) | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
| KR20190132405A (ko) | 2017-03-15 | 2019-11-27 | 모더나티엑스, 인크. | 치료제의 세포내 전달을 위한 화합물 및 조성물 |
| WO2018170270A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
| MA47787A (fr) | 2017-03-15 | 2020-01-22 | Modernatx Inc | Vaccin contre le virus respiratoire syncytial |
| ES3020935T3 (en) | 2017-03-15 | 2025-05-23 | Modernatx Inc | Lipid nanoparticle formulation |
| WO2018170347A1 (en) | 2017-03-17 | 2018-09-20 | Modernatx, Inc. | Zoonotic disease rna vaccines |
| WO2018175783A1 (en) | 2017-03-22 | 2018-09-27 | Modernatx, Inc. | Rna bacterial vaccines |
| WO2018187590A1 (en) | 2017-04-05 | 2018-10-11 | Modernatx, Inc. | Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins |
| WO2018200737A1 (en) | 2017-04-26 | 2018-11-01 | Modernatx, Inc. | Herpes simplex virus vaccine |
| US12077501B2 (en) | 2017-06-14 | 2024-09-03 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| WO2018232355A1 (en) | 2017-06-15 | 2018-12-20 | Modernatx, Inc. | Rna antibodies |
| WO2018232357A1 (en) | 2017-06-15 | 2018-12-20 | Modernatx, Inc. | Rna formulations |
| EP3658134A4 (en) | 2017-07-24 | 2021-05-05 | Pharmosa Biopharm Inc. | LIPOSOME COMPOSITIONS WITH WEAK ACID MEDICINAL PRODUCTS AND USES THEREOF |
| WO2019036683A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | ANALYTICAL METHODS BY HPLC |
| CN111212905A (zh) | 2017-08-18 | 2020-05-29 | 摩登纳特斯有限公司 | Rna聚合酶变体 |
| WO2019036670A2 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | EFFECTIVE MRNA VACCINES |
| WO2019036685A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | METHODS FOR HPLC ANALYSIS |
| WO2019046809A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | METHODS OF MANUFACTURING LIPID NANOPARTICLES |
| US10653767B2 (en) | 2017-09-14 | 2020-05-19 | Modernatx, Inc. | Zika virus MRNA vaccines |
| DK3703658T3 (da) | 2017-10-31 | 2022-07-18 | Astrazeneca Ab | Lipidnanopartikler til administration af modificeret rna, der koder for et vegf-a-polypeptid |
| US20190192646A1 (en) | 2017-11-03 | 2019-06-27 | Modernatx, Inc. | Salmonella vaccines |
| CA3083102A1 (en) | 2017-11-21 | 2019-05-31 | Modernatx, Inc. | Epstein-barr virus vaccines |
| WO2019148101A1 (en) | 2018-01-29 | 2019-08-01 | Modernatx, Inc. | Rsv rna vaccines |
| DE202019006199U1 (de) | 2018-04-17 | 2026-01-12 | CureVac SE | Neue RSV-RNA-Moleküle und Zusammensetzungen für die Impfung |
| AU2019275068B2 (en) | 2018-05-24 | 2024-09-26 | Translate Bio, Inc. | Thioester cationic lipids |
| SG11202012770RA (en) | 2018-06-27 | 2021-01-28 | Modernatx Inc | Personalized cancer vaccine epitope selection |
| US12109310B2 (en) | 2018-06-28 | 2024-10-08 | Hadi Valadi | Exosome extracellular vesicles and methods of use |
| KR20210091120A (ko) | 2018-08-29 | 2021-07-21 | 트랜슬레이트 바이오 인코포레이티드 | Mrna-로딩된 지질 나노입자를 제조하는 개선된 공정 |
| AU2019338557A1 (en) | 2018-09-13 | 2021-03-25 | Modernatx, Inc. | Modified mRNA for the treatment of progressive familial intrahepatic cholestasis disorders |
| WO2020061367A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| US12151029B2 (en) | 2018-09-19 | 2024-11-26 | Modernatx, Inc. | PEG lipids and uses thereof |
| AU2019345067A1 (en) | 2018-09-19 | 2021-04-08 | Modernatx, Inc. | High-purity peg lipids and uses thereof |
| WO2020061457A1 (en) | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| CN113166783B (zh) | 2018-10-09 | 2024-10-11 | 不列颠哥伦比亚大学 | 包含无有机溶剂和去污剂的转染活性囊泡的组合物和系统以及与之相关的方法 |
| KR20210090634A (ko) | 2018-10-19 | 2021-07-20 | 트랜슬레이트 바이오 인코포레이티드 | 전령 rna의 무펌프 캡슐화 |
| CA3118947A1 (en) | 2018-11-07 | 2020-05-14 | Modernatx, Inc. | Rna cancer vaccines |
| MX2021009245A (es) | 2019-01-31 | 2021-11-12 | Modernatx Inc | Metodos de preparacion de nanoparticulas lipidicas. |
| US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
| JP2022521094A (ja) | 2019-02-20 | 2022-04-05 | モデルナティエックス インコーポレイテッド | 共転写キャッピング用ｒｎａポリメラーゼバリアント |
| CN113874502A (zh) | 2019-03-11 | 2021-12-31 | 摩登纳特斯有限公司 | 补料分批体外转录方法 |
| WO2020190750A1 (en) | 2019-03-15 | 2020-09-24 | Modernatx, Inc. | Hiv rna vaccines |
| EP3968952A1 (en) | 2019-05-14 | 2022-03-23 | Translate Bio, Inc. | Improved process of preparing mrna-loaded lipid nanoparticles |
| JP2022535006A (ja) | 2019-05-31 | 2022-08-04 | モデルナティエックス インコーポレイテッド | 増殖ｔ細胞アッセイ |
| ES2992127T3 (es) | 2019-07-08 | 2024-12-09 | Translate Bio Inc | Nanopartículas lipídicas cargadas de ARNm mejoradas y sus procesos de fabricación |
| WO2021016430A1 (en) | 2019-07-23 | 2021-01-28 | Translate Bio, Inc. | Stable compositions of mrna-loaded lipid nanoparticles and processes of making |
| CN114269918A (zh) | 2019-08-14 | 2022-04-01 | 摩登纳特斯有限公司 | 用于纯化体外转录的下游产物的方法 |
| JP2022547313A (ja) | 2019-09-11 | 2022-11-11 | モデルナティエックス インコーポレイテッド | ヒトサイトメガロウイルスワクチン |
| MX2022003269A (es) | 2019-09-19 | 2022-07-04 | Modernatx Inc | Compuestos lipidicos de cola ramificada y composiciones para la administracion intracelular de agentes terapeuticos. |
| CA3155014A1 (en) | 2019-09-19 | 2021-03-25 | Modernatx, Inc. | Cap guides and methods of use thereof for rna mapping |
| US12053551B2 (en) | 2019-12-20 | 2024-08-06 | Translate Bio, Inc. | Process of preparing mRNA-loaded lipid nanoparticles |
| EP4088281A4 (en) | 2020-01-10 | 2024-02-21 | ModernaTX, Inc. | VARIOUS AUTOCECODER FOR GENERATING BIOLOGICAL SEQUENCE |
| US20210228707A1 (en) | 2020-01-28 | 2021-07-29 | Modernatx, Inc. | Coronavirus rna vaccines |
| JP2023513073A (ja) | 2020-01-30 | 2023-03-30 | モデルナティエックス インコーポレイテッド | 呼吸器系ウイルス免疫化組成物 |
| CN116133652A (zh) | 2020-01-31 | 2023-05-16 | 摩登纳特斯有限公司 | 制备脂质纳米粒子的方法 |
| AU2021215938A1 (en) | 2020-02-07 | 2022-09-01 | Modernatx, Inc. | Sars-cov-2 mrna domain vaccines |
| WO2021173840A1 (en) | 2020-02-25 | 2021-09-02 | Translate Bio, Inc. | Improved processes of preparing mrna-loaded lipid nanoparticles |
| KR102924173B1 (ko) | 2020-04-09 | 2026-02-06 | 쑤저우 아보젠 바이오사이언시스 컴퍼니 리미티드 | 지질 나노입자 조성물 |
| WO2021211343A1 (en) | 2020-04-13 | 2021-10-21 | Modernatx, Inc. | Zika virus mrna vaccines |
| WO2021222304A1 (en) | 2020-04-27 | 2021-11-04 | Modernatx, Inc. | Sars-cov-2 rna vaccines |
| WO2021159130A2 (en) | 2020-05-15 | 2021-08-12 | Modernatx, Inc. | Coronavirus rna vaccines and methods of use |
| US20230181481A1 (en) | 2020-05-15 | 2023-06-15 | Modernatx, Inc. | Rna formulations for high volume distribution, and methods of using the same for treating covid-19 |
| EP4149425A1 (en) | 2020-05-15 | 2023-03-22 | Translate Bio, Inc. | Lipid nanoparticle formulations for mrna delivery |
| US20230190761A1 (en) | 2020-05-21 | 2023-06-22 | Modernatx, Inc. | Methylene blue stabilized mrna compositions |
| AU2021283934A1 (en) | 2020-06-05 | 2023-01-19 | Modernatx, Inc. | Bacterial strains for DNA production |
| TW202220637A (zh) | 2020-08-06 | 2022-06-01 | 美商現代公司 | 製備脂質奈米顆粒之方法 |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| WO2022067010A1 (en) | 2020-09-25 | 2022-03-31 | Modernatx, Inc. | Multi-proline-substituted coronavirus spike protein vaccines |
| US20220133631A1 (en) | 2020-10-12 | 2022-05-05 | Translate Bio, Inc. | Process of preparing ice-based lipid nanoparticles |
| US20220110884A1 (en) | 2020-10-12 | 2022-04-14 | Translate Bio, Inc. | Process of preparing mrna-loaded lipid nanoparticles |
| WO2022150717A1 (en) | 2021-01-11 | 2022-07-14 | Modernatx, Inc. | Seasonal rna influenza virus vaccines |
| US20240139309A1 (en) | 2021-01-15 | 2024-05-02 | Modernatx, Inc. | Variant strain-based coronavirus vaccines |
| JP2024503698A (ja) | 2021-01-15 | 2024-01-26 | モデルナティエックス インコーポレイテッド | 変異型株ベースのコロナウイルスワクチン |
| IL305644A (en) | 2021-03-05 | 2023-11-01 | Modernatx Inc | Vlp enteroviral vaccines |
| JP2024511179A (ja) | 2021-03-26 | 2024-03-12 | モデルナティエックス インコーポレイテッド | 百日咳ワクチン |
| EP4314000A1 (en) | 2021-03-31 | 2024-02-07 | ModernaTX, Inc. | Synthesis of trinucleotide and tetranucleotide caps for mrna production |
| EP4314046A4 (en) | 2021-04-01 | 2025-03-19 | ModernaTX, Inc. | Mucosal expression of antibody structures and isotypes by mRNA |
| EP4314332A2 (en) | 2021-04-01 | 2024-02-07 | ModernaTX, Inc. | Methods for identification and ratio determination of rna species in multivalent rna compositions |
| EP4322997A4 (en) | 2021-04-13 | 2025-02-26 | ModernaTX, Inc. | EPSTEIN-BARR VIRUS mRNA VACCINES |
| WO2022221336A1 (en) | 2021-04-13 | 2022-10-20 | Modernatx, Inc. | Respiratory syncytial virus mrna vaccines |
| AU2022258335A1 (en) | 2021-04-13 | 2023-11-23 | Modernatx, Inc. | Respiratory virus combination vaccines |
| WO2022221440A1 (en) | 2021-04-14 | 2022-10-20 | Modernatx, Inc. | Influenza-coronavirus combination vaccines |
| EP4329731A1 (en) | 2021-04-29 | 2024-03-06 | ModernaTX, Inc. | Lyophilization methods for preparing lipid formulated therapeutics |
| US20220363937A1 (en) | 2021-05-14 | 2022-11-17 | Armstrong World Industries, Inc. | Stabilization of antimicrobial coatings |
| EP4355891A4 (en) | 2021-06-14 | 2025-09-24 | Modernatx Inc | VACCINES AGAINST CORONAVIRUS GLYCOSYLATION VARIANTS |
| EP4355761A1 (en) | 2021-06-14 | 2024-04-24 | ModernaTX, Inc. | Mrna vaccines encoding flexible coronavirus spike proteins |
| WO2022266389A1 (en) | 2021-06-17 | 2022-12-22 | Modernatx, Inc. | Alternative rna purification strategies |
| WO2023283642A2 (en) | 2021-07-09 | 2023-01-12 | Modernatx, Inc. | Pan-human coronavirus concatemeric vaccines |
| US20240358819A1 (en) | 2021-07-09 | 2024-10-31 | Modernatx, Inc. | Pan-human coronavirus domain vaccines |
| US20240382581A1 (en) | 2021-07-09 | 2024-11-21 | Modernatx, Inc. | Pan-human coronavirus vaccines |
| TW202320736A (zh) | 2021-07-26 | 2023-06-01 | 美商現代公司 | 用於製備脂質奈米粒子組成物之製程 |
| TW202320737A (zh) | 2021-07-26 | 2023-06-01 | 美商現代公司 | 製備用於將酬載分子遞送至氣道上皮之脂質奈米粒子組成物之製程 |
-
2018
- 2018-08-31 WO PCT/US2018/049251 patent/WO2019046809A1/en not_active Ceased
- 2018-08-31 AU AU2018326799A patent/AU2018326799A1/en not_active Abandoned
- 2018-08-31 US US16/643,037 patent/US11744801B2/en active Active
- 2018-08-31 JP JP2020512372A patent/JP7275111B2/ja active Active
- 2018-08-31 CN CN201880062774.3A patent/CN111315359A/zh active Pending
- 2018-08-31 MX MX2020002348A patent/MX2020002348A/es unknown
- 2018-08-31 EP EP18778694.2A patent/EP3675817A1/en active Pending
- 2018-08-31 CA CA3073211A patent/CA3073211A1/en active Pending
-
2023
- 2023-05-02 JP JP2023076121A patent/JP2023093756A/ja active Pending
- 2023-06-21 US US18/338,485 patent/US12357575B2/en active Active
-
2025
- 2025-04-24 JP JP2025072087A patent/JP2025108727A/ja active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012505913A (ja) | 2008-10-16 | 2012-03-08 | マリーナ バイオテック，インコーポレイテッド | 遺伝子発現を抑制する治療におけるリポソームによる効率的な送達のプロセスおよび組成物 |
| JP2016515815A (ja) | 2013-03-15 | 2016-06-02 | ザ ユニバーシティ オブ ブリティッシュ コロンビア | 形質移入用の脂質ナノ粒子および関連方法 |
| JP2016535729A (ja) | 2013-10-22 | 2016-11-17 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | フェニルケトン尿症のためのｍＲＮＡ療法 |
| JP2016540769A (ja) | 2013-12-05 | 2016-12-28 | サイレンス・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 肺特異的送達用手段 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023093756A (ja) * | 2017-08-31 | 2023-07-04 | モデルナティエックス インコーポレイテッド | 脂質ナノ粒子の生成方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020002348A (es) | 2020-10-08 |
| US11744801B2 (en) | 2023-09-05 |
| WO2019046809A1 (en) | 2019-03-07 |
| US20200306191A1 (en) | 2020-10-01 |
| AU2018326799A1 (en) | 2020-02-27 |
| JP2025108727A (ja) | 2025-07-23 |
| CN111315359A (zh) | 2020-06-19 |
| CA3073211A1 (en) | 2019-03-07 |
| EP3675817A1 (en) | 2020-07-08 |
| JP2023093756A (ja) | 2023-07-04 |
| US12357575B2 (en) | 2025-07-15 |
| JP2020532528A (ja) | 2020-11-12 |
| US20240009131A1 (en) | 2024-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12357575B2 (en) | Methods of making lipid nanoparticles | |
| US12144895B2 (en) | Stabilized formulations of lipid nanoparticles | |
| JP7635131B2 (ja) | 脂質ナノ粒子の調製方法 | |
| EP3852728B1 (en) | Preparation of lipid nanoparticles and methods of administration thereof | |
| JP2022095702A (ja) | 脂質ナノ粒子の安定化製剤 | |
| KR20220133957A (ko) | 지질 나노입자의 제조 방법 | |
| AU2019277361B2 (en) | Messenger RNA vaccines and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210830 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210830 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220525 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220531 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220815 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221213 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230310 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230404 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230502 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7275111 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |